{"id":"sulphadoxine-pyrimethamine-amodiaquine-azithromycin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL682","moleculeType":"Small molecule","molecularWeight":"355.87"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sulphadoxine and pyrimethamine are a combination of two drugs that work synergistically to treat malaria. Sulphadoxine inhibits the growth of the malaria parasite by interfering with its ability to synthesize folic acid, while pyrimethamine targets the parasite's dihydrofolate reductase enzyme. Amodiaquine is another antimalarial drug that targets the parasite's heme detoxification pathway. Azithromycin, on the other hand, is a broad-spectrum antibiotic that targets a wide range of bacteria by inhibiting protein synthesis.","oneSentence":"Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:48.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated malaria"},{"name":"Prevention of malaria in areas with high transmission"}]},"trialDetails":[{"nctId":"NCT02211729","phase":"PHASE3","title":"A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2014-05","conditions":"Malaria, Respiratory Infections","enrollment":22090}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin","genericName":"Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria. Used for Treatment of uncomplicated malaria, Prevention of malaria in areas with high transmission.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}